Strongbridge Biopharma plc to Present at the JMP Securities Life Sciences Conference
June 06 2018 - 7:30AM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that management will
present at the JMP Securities Life Sciences Conference taking place
June 20-21, 2018 at the St. Regis in New York, NY.
Matthew Pauls, president and chief executive
officer of Strongbridge Biopharma, will provide a corporate
overview on Wednesday, June 20 at 12:00p.m. E.T. The presentation
will be webcast live and archived on the “Events &
Presentations” page in the investor section of the Company’s
website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs. Strongbridge's commercial portfolio within its rare
neuromuscular and rare endocrine franchises includes KEVEYIS®
(dichlorphenamide), the first and only FDA-approved treatment
for hyperkalemic, hypokalemic, and related variants of primary
periodic paralysis, and MACRILEN™ (macimorelin), the first and
only FDA-approved oral drug indicated for the diagnosis of
adult growth hormone deficiency. The Company’s rare endocrine
franchise also includes a clinical-stage pipeline of therapies:
RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor
currently being studied for the treatment of endogenous Cushing's
syndrome, and veldoreotide, a next-generation somatostatin analog
being investigated for the treatment of acromegaly and potential
additional applications in other conditions amenable to
somatostatin receptor activation.
Contacts:
Corporate and Media Relations Elixir Health
Public Relations Lindsay Rocco +1 862-596-1304
lrocco@elixirhealthpr.com
Investor RelationsUnited
States:Solebury Trout Marcy Nanus +1 646-378-2927
mnanus@soleburytrout.com
Europe:First HouseGeir Arne Drangeid +47 913 10
458strongbridgebio@firsthouse.no
USA 900 Northbrook Drive Suite 200 Trevose,
PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jul 2023 to Jul 2024